One Company That's Set to Win From Precision Medicine
In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up the biotech world to tons of new research and treatment opportunities. But the vast majority of clinical trials fail, and biotechs are very risky investments.
In this clip from Industry Focus: Healthcare, host Kristine Harjes and contributor Todd Campbell explain why most of the precision medicine space is risky for investors, and how Illumina (NASDAQ: ILMN) is one company that gets exposure to the industry without taking on that astronomically high failure risk.
A full transcript follows the video.
Source: Fool.com
Illumina Inc. Aktie
116,24 €
1,93 %
Die Community bevorzugt klar Illumina Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Community-Kursziel von 160 € für Illumina Inc. deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 116.24 € hin.
